Gerd holds board certified specializations in pathology, neuropathology, legal medicine. After his university career he was head for Drug Safety and Pharmacovigilance at Boehringer Mannheim (Germany), then head of Lead Optimization (Pharmacology, Toxicology, Kinetics, Metabolism and Clinical Phase I) at Hoechst Marion Roussel/Aventis (Paris/France); and head of preclinical research and development of ALTANA Pharma AG, Germany (Hamburg) until 2005. Gerd was for the European Industry (EFPIA) ICH-Topic Leader for Preclinical Safety Guidelines from 1989 to 2005 in the International Conferences on Harmonization. Further highlights during his career were: long-term Chairman of the German toxicology group (7er Kreis), 5 years chairman of ad hoc Safety Group of EFPIA, Brussels. Gerd received a Service Award 2004 by Drug Information Association, Co-Chairman of the Annual Meeting DIA 2007 in Vienna, and a Scientific Award 2010 by the Safety Pharmacology Society in Boston. Gerd is member of several scientific societies and organizations, and published more than 100 scientific papers. Gerd finalized more than 20 Expert Reports/Common Technical Documents for small molecules and biotechnology-derived compounds.
The selection of commercially viable drug candidates and advancing their development
toward worldwide markets is a complex and challenging task that requires people with a broad
range of different qualifications and drug development know-how.